KLCMU
HZNP

Kite Lake Capital Management (UK)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kite Lake Capital Management (UK)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,525,489
Closed -$176M – 24
2023
Q3 		$176M Buy
+1,525,489
New +$164M 16.51% 2

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kite Lake Capital Management (UK)'s HZNP Position: Q4 2023 in Review

Kite Lake Capital Management (UK) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,525,489 shares — an estimated $176M sold.

Kite Lake Capital Management (UK) first reported a position in HZNP in Q3 2023 and held it in 1 quarter. The position peaked at $176M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Kite Lake Capital Management (UK) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Kite Lake Capital Management (UK) sold 1,525,489 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $176M.
  • Kite Lake Capital Management (UK) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023 and held it in 1 quarter.
  • Kite Lake Capital Management (UK)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $176M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Kite Lake Capital Management (UK)'s 13F filing for Q4 2023, filed 14 Feb 2024.